MAP2K7 and melanoma: Before immune checkpoint inhibitors (ICIs), BRAF inhibitors and MEK inhibitors became available in the real world, DTIC, type I IFN and/or IL-2-based combined therapies were the main protocol for the treatment of advanced melanoma [1,2,4,5,6,11,12,13,14,15,16], although the efficacy of those protocols remained insufficient.